Search clinical trials for: Refractory melanoma

Total 12480 results

GeneMedicine Co., Ltd.

Recruiting

GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors

Renal Cell Carcinoma | Cervical Cancer | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Malignant Melanoma

Korea, Republic of
M.D. Anderson Cancer Center

Recruiting

Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients

ICB-refractory Melanoma

United States
N.N. Petrov National Medical Research Center of...

Recruiting

Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations (NТО-RAS)

Melanoma | Lung Cancer | Pancreas Cancer | Refractory Cancer | Colorectal Cancer Recurrent | RAS Mutation | Ras (Kras or Nras) Gene Mutation

Russian Federation
Diwakar Davar
Merck Sharp & Dohme LLC; Gateway for Cancer Research

Not yet recruiting

Pembrolizumab/Lenvatinib With and Without Responder-derived FMT in Relapsed/Refractory Melanoma

PD-1 Refractory Advanced Melanoma

United States
Sensei Biotherapeutics, Inc.
Regeneron Pharmaceuticals

Recruiting

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Melanoma | Sarcoma | Kidney Cancer | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Non Small Cell Lung Cancer | Metastatic Cancer | Bladder Cancer | Cervix Cancer | Advanced Solid Tumor | Advanced Cancer | Colon Cancer | Thyroid Cancer | Solid Tumor... and other conditions

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

Melanoma | Solid Tumor | Metastatic Cancer | Advanced Cancer | Head and Neck Squamous Cell Carcinoma | Kaposi Sarcoma | Merkel Cell Carcinoma | Angiosarcoma | Basal Cell Carcinoma | Extramammary Paget Disease | HNSCC | Refractory Cancer | Cutaneous Squamous Cell Carcinoma | BCC | Adnexal Carcinoma | BCC - Basal Cell Carcinoma and other conditions

United States
Vanderbilt-Ingram Cancer Center

Recruiting

Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors

Metastatic Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Refractory Melanoma

United States
GV20 Therapeutics

Recruiting

A Study of GV20-0251 in Patients With Solid Tumor Malignancies

Cholangiocarcinoma | Non-small Cell Lung Cancer | Endometrial Carcinoma | Head and Neck Carcinoma | Cutaneous Melanoma | Solid Tumor, Adult | Refractory Cancer | Adenocarcinoma of the Rectum | Bladder Urothelial Carcinoma | Adenocarcinoma of the Colon

United States
H. Lee Moffitt Cancer Center and Research Institute
Turnstone Biologics, Corp.

Recruiting

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

Metastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous Melanoma

United States
Lyell Immunopharma, Inc.

Recruiting

A Study to Investigate LYL845 in Adults With Solid Tumors

Melanoma | Colorectal Cancer | Non-small Cell Lung Cancer

United States
ModernaTX, Inc.

Recruiting

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Advanced Solid Tumors

United States, United Kingdom, Australia, Spain
TILT Biotherapeutics Ltd.

Recruiting

Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1 (AVENTIL)

Melanoma | Head and Neck Squamous Cell Carcinoma

United States, Finland
Shanghai Fengxian District Central Hospital
Shanghai Yuansong Biotechnology Co., LTD

Recruiting

Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study (YSCH-01)

Melanoma | Breast Cancer | Head and Neck Cancer | Lung Cancer | Bladder Cancer | Cervical Carcinoma | Ovarian Carcinoma

China
Rapa Therapeutics LLC

Recruiting

RAPA-201 Therapy of Solid Tumors

Breast Cancer | Head and Neck Cancer | Gastric Cancer | Solid Tumor | Bladder Cancer | Triple Negative Breast Cancer | Esophageal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Malignant Melanoma | Carcinoma of Unknown Primary | Squamous Cell Carcinoma of Larynx | Squamous Cell Carcinoma of Oral Cavity | Squamous Cell Carcinoma of Nasopharynx and other conditions

United States
Diwakar Davar
Arcus Biosciences, Inc.

Recruiting

Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma

Melanoma

United States
Fred Hutchinson Cancer Center
Amazon.com Services LLC

Recruiting

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC... and other conditions

United States
M.D. Anderson Cancer Center

Recruiting

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

Chondrosarcoma | Advanced Malignant Solid Neoplasm | Stage III Uterine Corpus Cancer AJCC v8 | Stage IV Uterine Corpus Cancer AJCC v8 | Stage IVA Uterine Corpus Cancer AJCC v8 | Stage IVB Uterine Corpus Cancer AJCC v8 | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous... and other conditions

United States
April Salama, M.D.
Merck Sharp & Dohme LLC; Olatec Therapeutics LLC

Recruiting

A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma

Melanoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Melanoma | Neuroblastoma | Pancreatic Ductal Adenocarcinoma | Refractory Malignant Solid Neoplasm | Endometrial Carcinoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Malignant Solid Neoplasm | Recurrent Non-Hodgkin Lymphoma | Recurrent Osteosarcoma | Refractory Ewing Sarcoma | Refractory... and other conditions

United States
NovalGen Ltd.

Recruiting

First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Non-small Cell Lung Cancer (NSCLC) | Small Lymphocytic Lymphoma | Malignant Melanoma | Chronic Lymphocytic Leukaemia

United Kingdom
Jonsson Comprehensive Cancer Center
Parker Institute for Cancer Immunotherapy; City of Hope National Medical Center and other collaborators

Recruiting

Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Metastatic Melanoma | Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Recruiting

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

Refractory Melanoma | HLA-A2 Positive Cells Present

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors

Metastatic Lung Non-Small Cell Carcinoma | Refractory Lung Non-Small Cell Carcinoma | Metastatic Melanoma | Stage IV Lung Cancer AJCC v8 | Unresectable Malignant Solid Neoplasm | Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Malignant Solid Neoplasm | Unresectable Melanoma | Clinical... and other conditions

United States
Gregory Daniels
Immunotherapy Foundation

Recruiting

Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors

Metastatic Melanoma | Metastatic Head and Neck Cancer | Locally Advanced Refractory/Recurrent Melanoma | Locally Advanced Refractory/Recurrent Head and Neck Cancer

United States
Immatics US, Inc.

Recruiting

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (ACTengine)

Cancer | Solid Tumor, Adult | Refractory Cancer | Recurrent Cancer

United States, Germany
Megan Daly, MD
Merck Sharp & Dohme LLC

Recruiting

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

Metastatic Renal Cell Carcinoma | Non Small Cell Lung Cancer | Metastatic Melanoma | Head and Neck Squamous Cell Carcinoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors

Refractory Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Cutaneous Melanoma | Recurrent Malignant Female Reproductive System Neoplasm | Refractory Malignant Female Reproductive System Neoplasm | Recurrent Lip and Oral Cavity Carcinoma | Recurrent Malignant Endocrine... and other conditions

United States
Taiga Biotechnologies, Inc.

Recruiting

Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors

Stage IV Melanoma | Stage III Melanoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Malignant Solid Neoplasm | Recurrent Melanoma | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Glioma | Hematopoietic and Lymphoid Cell Neoplasm | Melanoma | Lymphoma | Multiple Myeloma | Recurrent Ovarian Carcinoma | Breast Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Skin Carcinoma | Gastric Carcinoma | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory... and other conditions

United States, Puerto Rico, Guam
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Stage IV Uterine Corpus Cancer AJCC v8 | Endometrial Adenocarcinoma | Endometrioid Adenocarcinoma

United States, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

Metastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Refractory Melanoma | BRAF V600 Wild Type | Intracranial Melanoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Cutaneous Melanoma

United States
ModernaTX, Inc.
AstraZeneca

Active, not recruiting

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma | Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma

United States, Israel, Australia
MacroGenics

Active, not recruiting

A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors (Tamarack)

Melanoma | Non-small Cell Lung Cancer | Small-cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Anal Cancer | Malignant Melanoma | Non-small Cell Carcinoma | Oral Squamous Cell Carcinoma | Small Cell Carcinoma | Laryngeal Squamous Cell Carcinoma | Carcinoma, Squamous Cell of Head and Neck | Castration-Resistant... and other conditions

Spain, Australia, United States, Korea, Republic of, France, United Kingdom, Italy, Belgium, Poland
National Cancer Institute (NCI)

Active, not recruiting

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

Sarcoma | Metastatic Renal Cell Carcinoma | Metastatic Melanoma | Recurrent Renal Cell Carcinoma | Recurrent Melanoma | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Clinical Stage IV Cutaneous Melanoma... and other conditions

United States, Canada
Yana Najjar
Bristol-Myers Squibb; Pfizer

Active, not recruiting

Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma

Unresectable Melanoma | Advanced Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis Pharmaceuticals

Active, not recruiting

Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma

Melanoma | Unresectable Melanoma | Advanced Melanoma

United States
Pfizer

Active, not recruiting

Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (COLUMBUS)

Melanoma

Canada, United States, Spain, Germany, Korea, Republic of, Australia, Czechia, Netherlands, France, Hungary, United Kingdom, Switzerland, Singapore, Russian Federation, Italy, Japan, Israel, Brazil, Portugal, Mexico, Greece, Argen... and more
Seattle Children's Hospital

Active, not recruiting

B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

Melanoma | Soft Tissue Sarcoma | Carcinoma | Osteosarcoma | Ewing Sarcoma | Rhabdoid Tumor | Neuroblastoma | Retinoblastoma | Rhabdomyosarcoma | Wilms Tumor | Hepatoblastoma | Synovial Sarcoma | Desmoplastic Small Round Cell Tumor | Germ Cell Tumor | Pediatric Solid Tumor | Clear Cell Sarcoma | Malignant Peripheral Nerve Sheath...

United States
M.D. Anderson Cancer Center
Mologen AG

Active, not recruiting

Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies

Melanoma | Advanced Cancers

United States
Eli Lilly and Company

Active, not recruiting

A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (PACT)

Pancreatic Cancer | Solid Tumor | Cutaneous Melanoma | Microsatellite Instability-High (MSI-H) Solid Tumors | Breast Cancer (HR+HER2-)

France, Spain, Belgium, Korea, Republic of, United States, Taiwan, Canada
Istari Oncology, Inc.

Active, not recruiting

LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma

Melanoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

Sezary Syndrome | Refractory T-Cell Non-Hodgkin Lymphoma | Merkel Cell Carcinoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Extramammary Paget Disease | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Refractory Mature T-Cell and NK-Cell Non-Hodgkin... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
National Cancer Institute (NCI)

Active, not recruiting

Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies

Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm

United States
Neurogene Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer

Solid Tumor | Advanced Solid Tumor

United States, Australia, Canada
National Cancer Institute (NCI)
Celgene Corporation

Active, not recruiting

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

Glioma | Hematopoietic and Lymphoid Cell Neoplasm | Lymphoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Renal Cell Carcinoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer... and other conditions

United States, Canada
BioNTech SE
Regeneron Pharmaceuticals

Active, not recruiting

Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma

Unresectable Melanoma | Melanoma Stage IV | Melanoma Stage III

United States, Spain, Germany, Italy, Australia, United Kingdom, Poland
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

HIV Infection | Metastatic Renal Cell Carcinoma | Anatomic Stage III Breast Cancer AJCC v8 | Recurrent Ovarian Carcinoma | Metastatic Lung Non-Small Cell Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Melanoma | Recurrent Head and Neck Carcinoma | Recurrent Renal Cell Carcinoma | Advanced... and other conditions

United States

Search clinical trials for: Refractory melanoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Romania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations